We are live on
!
Find out more
WVP
Worth Venture Partners Portfolio holdings
AUM
$44.3M
1-Year Est. Return
34.55%
This Fund
S&P 500
This Quarter
Est. Return
-1.9%
1 Year Est. Return
+34.55%
3 Year Est. Return
+105.38%
5 Year Est. Return
+125.01%
10 Year Est. Return
–
AUM
$169M
AUM Growth
-$15.1M
(-8.2%)
Cap. Flow
-$71.7M
Cap. Flow
% of AUM
-42.56%
Top 10 Holdings %
Top 10 Hldgs %
33.65%
Holding
197
New
30
Increased
43
Reduced
28
Closed
35
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aspen Aerogels
ASPN
|
+$3.04M |
| 2 |
VCNX
Vaccinex, Inc. Common Stock
VCNX
|
+$2.57M |
| 3 |
ALIM
Alimera Sciences
ALIM
|
+$1.96M |
| 4 |
Ouster
OUST
|
+$1.74M |
| 5 |
Silicom
SILC
|
+$1.63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microchip Technology
MCHP
|
+$5.37M |
| 2 |
ANI Pharmaceuticals
ANIP
|
+$4.71M |
| 3 |
Aviat Networks
AVNW
|
+$1.76M |
| 4 |
Annovis Bio
ANVS
|
+$1.14M |
| 5 |
CMBM
Cambium Networks
CMBM
|
+$1.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 53.3% |
| 2 | Healthcare | 16.15% |
| 3 | Technology | 14.41% |
| 4 | Financials | 7.09% |
| 5 | Materials | 2.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SCPH
1
DELISTED
scPharmaceuticals
SCPH
| $3.84M | 2.28% |
539,665
+27,328
| +5% | +$215K |
|
|
2
Aspen Aerogels
ASPN
$417M
| $3.68M | 2.19% |
+428,367
| New | +$3.04M |
|
3
indie Semiconductor
INDI
$790M
| $3.37M | 2% |
534,753
+20,918
| +4% | +$162K |
|
|
TGAN
4
DELISTED
Transphorm, Inc. Common Stock
TGAN
| $2.56M | 1.52% |
1,152,278
+50,598
| +5% | +$141K |
|
5
TELA Bio
TELA
$38.1M
| $2.51M | 1.49% |
314,220
-99,021
| -24% | -$920K |
|
6
Apollo Global Management
APO
$78.7B
| $2.47M | 1.46% |
27,503
| – | – |
|
|
7
Aviat Networks
AVNW
$251M
| $2.34M | 1.39% |
75,046
-55,530
| -43% | -$1.76M |
|
8
Progressive
PGR
$125B
| $2.12M | 1.26% |
15,247
| – | – |
|
9
Everspin Technologies
MRAM
$417M
| $2.08M | 1.24% |
211,862
-2,350
| -1% | -$22.7K |
|
10
Franklin Covey
FC
$213M
| $2.07M | 1.23% |
48,178
+3,855
| +9% | +$171K |
|
11
Biodesix
BDSX
$286M
| $1.98M | 1.18% |
60,118
-3,057
| -5% | -$84.9K |
|
12
OneMain Financial
OMF
$7.36B
| $1.94M | 1.15% |
48,433
| – | – |
|
|
ALIM
13
DELISTED
Alimera Sciences
ALIM
| $1.84M | 1.09% |
+593,709
| New | +$1.96M |
|
14
Capital One
COF
$132B
| $1.71M | 1.02% |
17,661
| – | – |
|
15
Hilton Grand Vacations
HGV
$3.2B
| $1.61M | 0.95% |
39,541
| – | – |
|
|
16
Ouster
OUST
$2.75B
| $1.59M | 0.94% |
+314,910
| New | +$1.74M |
|
17
Myomo
MYO
$53.5M
| $1.55M | 0.92% |
1,397,861
+278,544
| +25% | +$237K |
|
18
Apyx Medical
APYX
$126M
| $1.48M | 0.88% |
462,606
+153,144
| +49% | +$714K |
|
|
19
Silicom
SILC
$265M
| $1.43M | 0.85% |
+54,880
| New | +$1.63M |
|
|
BWAY
20
Brainsway
BWAY
$567M
| $1.36M | 0.81% |
673,286
+38,090
| +6% | +$58.8K |
|
21
GSI Technology
GSIT
$213M
| $1.35M | 0.8% |
499,400
| – | – |
|
22
Lightpath Technologies
LPTH
$663M
| $1.35M | 0.8% |
929,611
+83,649
| +10% | +$140K |
|
23
Raymond James Financial
RJF
$34.2B
| $1.31M | 0.78% |
13,035
| – | – |
|
24
Markel Group
MKL
$22.3B
| $1.23M | 0.73% |
835
| – | – |
|
25
Abeona Therapeutics
ABEO
$340M
| $1.18M | 0.7% |
281,280
+121,969
| +77% | +$462K |
|
Similar funds
CWM
RA
CAM
GAFA
G
CF
GP
CUIC
Worth Venture Partners's Q3 2023 Portfolio in Review
As of Q3 2023, Worth Venture Partners held 197 positions worth $169M, down 8.2% from $184M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Worth Venture Partners withdrew a net $71.7M in Q3 2023, closing 35 positions and reducing 28 holdings. Its most notable exit was ANI Pharmaceuticals, an estimated $4.71M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 53% of assets, up from 50% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Worth Venture Partners opened a new position in Aspen Aerogels worth $3.68M.
- Worth Venture Partners's largest Q3 2023 buy was Aspen Aerogels: 428,367 shares worth $3.68M.
- Worth Venture Partners added most to Vaccinex, Inc. Common Stock in Q3 2023, an estimated $2.57M increase.
- Worth Venture Partners's biggest Q3 2023 reduction was Microchip Technology, cutting an estimated $5.37M.
- Worth Venture Partners fully exited ANI Pharmaceuticals in Q3 2023, selling an estimated $4.71M.
- Worth Venture Partners's ten largest holdings make up 34% of its $169M portfolio in Q3 2023.
- Worth Venture Partners opened 30 new positions and closed 35 in Q3 2023.
- Worth Venture Partners's portfolio value fell 8.2% quarter-over-quarter to $169M.
Based on Worth Venture Partners's 13F filing for Q3 2023, filed 15 Nov 2023.